Nanoparticles and targeted drug delivery in cancer therapy

•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach. Surgery, chemotherapy, radiotherapy, and hormone therapy are the main...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunology letters 2017-10, Vol.190, p.64-83
Hauptverfasser: Bahrami, Behdokht, Hojjat-Farsangi, Mohammad, Mohammadi, Hamed, Anvari, Enayat, Ghalamfarsa, Ghasem, Yousefi, Mehdi, Jadidi-Niaragh, Farhad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 83
container_issue
container_start_page 64
container_title Immunology letters
container_volume 190
creator Bahrami, Behdokht
Hojjat-Farsangi, Mohammad
Mohammadi, Hamed
Anvari, Enayat
Ghalamfarsa, Ghasem
Yousefi, Mehdi
Jadidi-Niaragh, Farhad
description •Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach. Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.
doi_str_mv 10.1016/j.imlet.2017.07.015
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_495055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165247817301761</els_id><sourcerecordid>1925271859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</originalsourceid><addsrcrecordid>eNp9kU1P3DAQhi1EVbbQX4BU5cglW38mdiUOCNEPCZULnC3HMwEv2SS1E9D-e7zdhZ6KNJJH1vPOO5qXkFNGl4yy6utqGdYdTktOWb2kuZg6IAuma1NSJfkhWWRKlVzW-oh8SmlFMyGk-EiOuK4rKo1ZkG-_XT-MLk7Bd5gK10MxuXiPE0IBcb4vALvwhHFThL7wrvcYi-kBoxs3J-RD67qEn_fvMbn7fnV7-bO8vvnx6_LiuvRS1lOpleYAogEpBFNtzcAbX1XgQDEAw7WpKoPOe95q13BVUWM0NDVtuVPCO3FMyt3c9Izj3NgxhrWLGzu4YPdfj7lDK42iSmXe_Jcf4wD_RK9CJirNNVcya8922gz-mTFNdh2Sx65zPQ5zssxwxWumlcmo2KE-DilFbN-MGLXbgOzK_g3IbgOyNBfbLvdlbzA3a4Q3zWsiGTjfAZhP-hQw2uQD5rtDiOgnC0N41-AF9mqkBw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925271859</pqid></control><display><type>article</type><title>Nanoparticles and targeted drug delivery in cancer therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bahrami, Behdokht ; Hojjat-Farsangi, Mohammad ; Mohammadi, Hamed ; Anvari, Enayat ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Jadidi-Niaragh, Farhad</creator><creatorcontrib>Bahrami, Behdokht ; Hojjat-Farsangi, Mohammad ; Mohammadi, Hamed ; Anvari, Enayat ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Jadidi-Niaragh, Farhad</creatorcontrib><description>•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach. Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.</description><identifier>ISSN: 0165-2478</identifier><identifier>ISSN: 1879-0542</identifier><identifier>EISSN: 1879-0542</identifier><identifier>DOI: 10.1016/j.imlet.2017.07.015</identifier><identifier>PMID: 28760499</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Cancer immunotherapy ; Drug Delivery Systems ; Drug-Related Side Effects and Adverse Reactions - prevention &amp; control ; Humans ; Medicin och hälsovetenskap ; Nanoparticles ; Nanoparticles - therapeutic use ; Neoplasms - drug therapy ; Targeted drug delivery</subject><ispartof>Immunology letters, 2017-10, Vol.190, p.64-83</ispartof><rights>2017 European Federation of Immunological Societies</rights><rights>Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</citedby><cites>FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.imlet.2017.07.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28760499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:136828254$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Bahrami, Behdokht</creatorcontrib><creatorcontrib>Hojjat-Farsangi, Mohammad</creatorcontrib><creatorcontrib>Mohammadi, Hamed</creatorcontrib><creatorcontrib>Anvari, Enayat</creatorcontrib><creatorcontrib>Ghalamfarsa, Ghasem</creatorcontrib><creatorcontrib>Yousefi, Mehdi</creatorcontrib><creatorcontrib>Jadidi-Niaragh, Farhad</creatorcontrib><title>Nanoparticles and targeted drug delivery in cancer therapy</title><title>Immunology letters</title><addtitle>Immunol Lett</addtitle><description>•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach. Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer immunotherapy</subject><subject>Drug Delivery Systems</subject><subject>Drug-Related Side Effects and Adverse Reactions - prevention &amp; control</subject><subject>Humans</subject><subject>Medicin och hälsovetenskap</subject><subject>Nanoparticles</subject><subject>Nanoparticles - therapeutic use</subject><subject>Neoplasms - drug therapy</subject><subject>Targeted drug delivery</subject><issn>0165-2478</issn><issn>1879-0542</issn><issn>1879-0542</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1P3DAQhi1EVbbQX4BU5cglW38mdiUOCNEPCZULnC3HMwEv2SS1E9D-e7zdhZ6KNJJH1vPOO5qXkFNGl4yy6utqGdYdTktOWb2kuZg6IAuma1NSJfkhWWRKlVzW-oh8SmlFMyGk-EiOuK4rKo1ZkG-_XT-MLk7Bd5gK10MxuXiPE0IBcb4vALvwhHFThL7wrvcYi-kBoxs3J-RD67qEn_fvMbn7fnV7-bO8vvnx6_LiuvRS1lOpleYAogEpBFNtzcAbX1XgQDEAw7WpKoPOe95q13BVUWM0NDVtuVPCO3FMyt3c9Izj3NgxhrWLGzu4YPdfj7lDK42iSmXe_Jcf4wD_RK9CJirNNVcya8922gz-mTFNdh2Sx65zPQ5zssxwxWumlcmo2KE-DilFbN-MGLXbgOzK_g3IbgOyNBfbLvdlbzA3a4Q3zWsiGTjfAZhP-hQw2uQD5rtDiOgnC0N41-AF9mqkBw</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Bahrami, Behdokht</creator><creator>Hojjat-Farsangi, Mohammad</creator><creator>Mohammadi, Hamed</creator><creator>Anvari, Enayat</creator><creator>Ghalamfarsa, Ghasem</creator><creator>Yousefi, Mehdi</creator><creator>Jadidi-Niaragh, Farhad</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20171001</creationdate><title>Nanoparticles and targeted drug delivery in cancer therapy</title><author>Bahrami, Behdokht ; Hojjat-Farsangi, Mohammad ; Mohammadi, Hamed ; Anvari, Enayat ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Jadidi-Niaragh, Farhad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer immunotherapy</topic><topic>Drug Delivery Systems</topic><topic>Drug-Related Side Effects and Adverse Reactions - prevention &amp; control</topic><topic>Humans</topic><topic>Medicin och hälsovetenskap</topic><topic>Nanoparticles</topic><topic>Nanoparticles - therapeutic use</topic><topic>Neoplasms - drug therapy</topic><topic>Targeted drug delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bahrami, Behdokht</creatorcontrib><creatorcontrib>Hojjat-Farsangi, Mohammad</creatorcontrib><creatorcontrib>Mohammadi, Hamed</creatorcontrib><creatorcontrib>Anvari, Enayat</creatorcontrib><creatorcontrib>Ghalamfarsa, Ghasem</creatorcontrib><creatorcontrib>Yousefi, Mehdi</creatorcontrib><creatorcontrib>Jadidi-Niaragh, Farhad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Immunology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bahrami, Behdokht</au><au>Hojjat-Farsangi, Mohammad</au><au>Mohammadi, Hamed</au><au>Anvari, Enayat</au><au>Ghalamfarsa, Ghasem</au><au>Yousefi, Mehdi</au><au>Jadidi-Niaragh, Farhad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoparticles and targeted drug delivery in cancer therapy</atitle><jtitle>Immunology letters</jtitle><addtitle>Immunol Lett</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>190</volume><spage>64</spage><epage>83</epage><pages>64-83</pages><issn>0165-2478</issn><issn>1879-0542</issn><eissn>1879-0542</eissn><abstract>•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach. Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28760499</pmid><doi>10.1016/j.imlet.2017.07.015</doi><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-2478
ispartof Immunology letters, 2017-10, Vol.190, p.64-83
issn 0165-2478
1879-0542
1879-0542
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_495055
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Antineoplastic Agents - therapeutic use
Cancer immunotherapy
Drug Delivery Systems
Drug-Related Side Effects and Adverse Reactions - prevention & control
Humans
Medicin och hälsovetenskap
Nanoparticles
Nanoparticles - therapeutic use
Neoplasms - drug therapy
Targeted drug delivery
title Nanoparticles and targeted drug delivery in cancer therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A42%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoparticles%20and%20targeted%20drug%20delivery%20in%20cancer%20therapy&rft.jtitle=Immunology%20letters&rft.au=Bahrami,%20Behdokht&rft.date=2017-10-01&rft.volume=190&rft.spage=64&rft.epage=83&rft.pages=64-83&rft.issn=0165-2478&rft.eissn=1879-0542&rft_id=info:doi/10.1016/j.imlet.2017.07.015&rft_dat=%3Cproquest_swepu%3E1925271859%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925271859&rft_id=info:pmid/28760499&rft_els_id=S0165247817301761&rfr_iscdi=true